Amneal Pharma up after US FDA approves sodium oxybate solution

Amneal Pharmaceuticals

11/09/2025 15:13

** Shares of drugmaker Amneal Pharmaceuticals AMRX.O rise 2% to $10.02

** Company says the U.S. FDA has approved Amneal's sodium oxybate oral solution for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy

** Amneal's solution is a generic version of Jazz Pharmaceuticals' JAZZ.O sleep disorder drug, Xyrem

** Narcolepsy is a chronic neurological disorder that disrupts the body's ability to regulate sleep-wake cycles

** Amneal says it had previously been distributing an authorized generic of sodium oxybate oral solution in limited quantities

** Including session moves, stock up 25.6% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))